Eisai 2012 First Quarter Aricept Sales Down 20%
This article was originally published in PharmAsia News
Eisai announced first quarter results August 1, and domestic sales of the company’s flagship Alzheimer drug Aricept, launched in November 2011 as a generic drug, decreased by 23.9% as prices of the drug decreased by 16%.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.